Mission Pharmacal Company, a leader in the medical management of kidney stone disease and provider of a variety of high-quality healthcare products, is pleased to announce the reintroduction of Lithostat® (acetohydroxamic acid) for use as an adjunctive therapy with antibiotic therapy for struvite (infection) kidney stones. As of September 7, Mission is again offering this product with significant improvements in service for the patients who rely on it and their healthcare providers.